Patients with advanced stages of T2DM, although technically classified as T2DM, exhibit key pathophysiological characteristics of T1DM, including pronounced glycemic variability, strong dependence on exogenous insulin treatment, marked metabolic fragility, and a heightened risk of hypoglycemia and ketoacidosis. This evidence concerns the gene INS and Hypoglycemia.